Immuneering Corp (IMRX) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $128.65M | +255.9% |
| 2024 | $36.14M | -39.2% |
| 2023 | $59.41M | -18.2% |
| 2022 | $72.64M | -3.0% |
| 2021 | $74.89M | +101.9% |
| 2020 | $37.09M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $128.65M | +255.9% |
| 2024 | $36.14M | -39.2% |
| 2023 | $59.41M | -18.2% |
| 2022 | $72.64M | -3.0% |
| 2021 | $74.89M | +101.9% |
| 2020 | $37.09M | — |